17:34 , Feb 3, 2017 |  BC Week In Review  |  Financial News

Cantabio completes private placement of convertible debentures

On Feb. 2, neurodegenerative disease company Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) raised $300,000 in debentures in the first tranche of a planned $600,000 private placement with Yorkville Advisors Global. The one-year debentures bear 5% interest and...
07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Chaperoning the DJ

  In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Company News

Cantabio, Purdue University deal

Cantabio and the university’s Purdue Research Foundation partnered to evaluate small molecule chaperone candidates from the biotech that target DJ-1 (PARK7) to treat neurodegenerative diseases, including Parkinson’s disease (PD). Cantabio will have access to resulting...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Cantabio, University of Antioquia deal

Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s candidates and cellular...